The new company, Anthos Therapeutics, will start by advancing a Novartis antibody that targets two clotting factors. The idea is to develop a drug that treats blood clots in acute and chronic situations to prevent a variety of cardiovascular disorders.
The company is backed by a $250 million investment from Blackstone, which will control the company. Novartis will have a minority stake.
Read the full report here.
More articles on pharmacy:
Viewpoint: It’s time for pharma to have its ‘tobacco moment’
Top 10 fatal or harmful prescribing errors
‘Wacky’ rebate system to blame for high patient drug prices, FDA chief says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.